ערך בספרים למניה: Ocean Biomedical, Inc. (OCEA)

Net book value per share helps determine the actual assets of a business, and -2.80 shows the level of this metric. Ocean Biomedical, Inc. (OCEA) develops immune technologies through university partnerships to combat malaria and cancer. The discovery licensing model ensures high scalability via royalties without the costs of manufacturing plants. However, a revenue deficit during the testing stage forces the company to constantly seek external capital.

For Ocean Biomedical, Inc. (OCEA), this indicator determines the value of net assets available to shareholders by dividing total equity by the number of shares outstanding. In the context of vaccine and therapy development, this metric reflects the capitalization of intellectual property and patents. By analyzing the trend in book value per share, an investor can assess the actual quality of assets and the risk of sudden impairment.